• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Foghorn Therapeutics Inc. - Common Stock (NQ:FHTX)

4.860 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 4.600 (100)
Ask (Size) 4.800 (1,000)
Prev. Close 4.860
Today's Range 4.860 - 4.860
52wk Range 3.270 - 6.950
Shares Outstanding 36,936,886
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Targets Next Wave of DNA Damage Response Cancer Therapies
June 22, 2026
Via Investor Brand Network
Topics Artificial Intelligence
Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
June 22, 2026
Via Investor Brand Network

Performance

YTD
-6.4%
-6.4%
1 Month
+22.3%
+22.3%
3 Month
+10.0%
+10.0%
6 Month
-6.4%
-6.4%
1 Year
+3.4%
+3.4%

More News

Read More
News headline image
Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
June 05, 2026
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May
May 12, 2026
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
May 07, 2026
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
April 21, 2026
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
April 09, 2026
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
March 11, 2026
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
February 24, 2026
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
February 23, 2026
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
February 03, 2026
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
January 13, 2026
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
January 09, 2026
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
November 25, 2025
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
This Aardvark Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday ↗
November 07, 2025
Via Benzinga
News headline image
Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update
November 05, 2025
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
These stocks are gapping in today's session ↗
November 04, 2025
Via Chartmill
News headline image
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
November 03, 2025
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs
October 30, 2025
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit
October 16, 2025
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
August 27, 2025
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
August 11, 2025
Via Benzinga
News headline image
Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update
August 05, 2025
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences
May 22, 2025
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update
May 14, 2025
From Foghorn Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Foghorn Therapeutics Inc. - Common Stock publicly traded?
Yes, Foghorn Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Foghorn Therapeutics Inc. - Common Stock trade on?
Foghorn Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Foghorn Therapeutics Inc. - Common Stock?
The ticker symbol for Foghorn Therapeutics Inc. - Common Stock is FHTX on the Nasdaq Stock Market
What is the current price of Foghorn Therapeutics Inc. - Common Stock?
The current price of Foghorn Therapeutics Inc. - Common Stock is 4.860
When was Foghorn Therapeutics Inc. - Common Stock last traded?
The last trade of Foghorn Therapeutics Inc. - Common Stock was at 06/29/26 04:00 PM ET
What is the market capitalization of Foghorn Therapeutics Inc. - Common Stock?
The market capitalization of Foghorn Therapeutics Inc. - Common Stock is 179.51M
How many shares of Foghorn Therapeutics Inc. - Common Stock are outstanding?
Foghorn Therapeutics Inc. - Common Stock has 180M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap